Corvus Pharmaceuticals Inc (CRVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has a cash flow conversion efficiency ratio of -0.150x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.19 Million) by net assets ($61.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Corvus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CRVS total debt and obligations for a breakdown of total debt and financial obligations.
Corvus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WuXi Xinje Electric Co Ltd
SHG:603416
|
0.001x |
|
Ziff Davis Inc
NASDAQ:ZD
|
0.077x |
|
HyUnion Holding Co Ltd
SHE:002537
|
0.017x |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
N/A |
|
SK Reit Co Ltd
KO:395400
|
N/A |
|
Befesa SA
XETRA:BFSA
|
0.052x |
|
China Modern Dairy Holdings Ltd
F:07M
|
0.109x |
|
Jsti Group
SHE:300284
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Corvus Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.20 Million | $-32.80 Million | -0.536x | +31.36% |
| 2024-12-31 | $32.57 Million | $-25.42 Million | -0.781x | -26.17% |
| 2023-12-31 | $38.68 Million | $-23.93 Million | -0.619x | -28.48% |
| 2022-12-31 | $56.12 Million | $-27.02 Million | -0.482x | -27.44% |
| 2021-12-31 | $97.16 Million | $-36.72 Million | -0.378x | +21.61% |
| 2020-12-31 | $72.15 Million | $-34.78 Million | -0.482x | +8.15% |
| 2019-12-31 | $71.11 Million | $-37.32 Million | -0.525x | -41.28% |
| 2018-12-31 | $110.34 Million | $-40.99 Million | -0.371x | +31.80% |
| 2017-12-31 | $84.83 Million | $-46.21 Million | -0.545x | -159.68% |
| 2016-12-31 | $132.80 Million | $-27.86 Million | -0.210x | -157.59% |
| 2015-12-31 | $-31.10 Million | $-11.33 Million | 0.364x | -44.70% |
| 2014-12-31 | $-159.00K | $-104.73K | 0.659x | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more